| Postherpetic neuralgia
Horizant vs Gralise
Side-by-side clinical, coverage, and cost comparison for postherpetic neuralgia.Deep comparison between: Horizant vs Gralise with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsGralise has a higher rate of injection site reactions vs Horizant based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Gralise but not Horizant, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Horizant
Gralise
At A Glance
Oral
Once or twice daily
Alpha-2-delta ligand
Oral
Once daily
GABA analogue
Indications
- Restless Legs Syndrome
- Postherpetic neuralgia
- Postherpetic neuralgia
Dosing
Restless Legs Syndrome 600 mg orally once daily at about 5 PM; dose adjustments required based on creatinine clearance in renal impairment; not recommended for patients on hemodialysis.
Postherpetic neuralgia Initiated at 600 mg orally in the morning for 3 days, then increased to 600 mg twice daily (1,200 mg/day); dose adjustments required based on creatinine clearance in renal impairment.
Postherpetic neuralgia Titrate to 1,800 mg once daily orally with the evening meal over 15 days (300 mg Day 1, 600 mg Day 2, 900 mg Days 3-6, 1,200 mg Days 7-10, 1,500 mg Days 11-14, 1,800 mg Day 15); swallow tablets whole, do not crush, split, or chew; if discontinuing, taper over at least 1 week.
Renal impairment Adjust dose for CrCl 30-60 mL/min (600-1,800 mg once daily); do not use in patients with CrCl <30 mL/min or on hemodialysis.
Contraindications
—
- Demonstrated hypersensitivity to gabapentin or any excipient of GRALISE
Adverse Reactions
Most common (>=5%) Somnolence/sedation, dizziness, headache, fatigue, nausea, irritability
Serious Suicidal behavior and ideation, seizures with abrupt or rapid discontinuation, respiratory depression, drug reaction with eosinophilia and systemic symptoms (DRESS)/multiorgan hypersensitivity
Postmarketing Breast enlargement, gynecomastia, elevated creatine kinase, bullous pemphigoid, life-threatening or fatal respiratory depression (with opioids or CNS depressants or underlying respiratory impairment), withdrawal symptoms including seizures, depression, anxiety, insomnia, and nausea
Most common (>=1%) Dizziness, somnolence, headache, peripheral edema, diarrhea, dry mouth, nasopharyngitis, weight increased, pain in extremity, back pain, urinary tract infection, constipation, dyspepsia, vertigo, pain, lethargy
Serious Suicidal behavior and ideation, respiratory depression, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/multiorgan hypersensitivity, adverse reactions with abrupt or rapid discontinuation
Postmarketing Angioedema, bullous pemphigoid, erythema multiforme, Stevens-Johnson syndrome, hyponatremia, jaundice, movement disorder, elevated liver function tests, elevated creatine kinase, withdrawal symptoms (seizures, depression, suicidal ideation and behavior, agitation, confusion), life-threatening or fatal respiratory depression (with opioids or CNS depressants)
Pharmacology
Gabapentin enacarbil is a prodrug of gabapentin that undergoes extensive first-pass hydrolysis after oral absorption; gabapentin binds with high affinity to the alpha-2-delta subunit of voltage-activated calcium channels, though its precise mechanism of action in RLS and PHN is unknown.
Gabapentin is a GABA analogue whose analgesic mechanism of action is unknown; in animal models it prevents allodynia and hyperalgesia, does not modify GABA receptor binding or GABA metabolism, and is hypothesized to antagonize thrombospondin binding to the alpha-2-delta-1 subunit of voltage-activated calcium channels involved in excitatory synapse formation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Horizant
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
Gralise
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Horizant
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Gralise
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Horizant
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Gralise
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Horizant.
No savings programs available for Gralise.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
HorizantView full Horizant profile
GraliseView full Gralise profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.